Hormonal status of patients after surgical treatment of fibrocystic mastopathy

Ю. Я. Присташ


The purpose of the study was to investigate the efficacy of Mastodynon® in terms of indications in elevated doses versus the standard dose.

Materials and methods. Data were analyzed for 60 patients after surgical treatment of fibrocystic mastopathy. Depending on the postoperative therapy received by the patients, they were divided into three equal groups. Patients of Group I were observed in accordance with the standards established in mammal practice and did not receive special agents that affect hormonal homeostasis. Patients of Group II in addition to observation received Mastodynon® (1 tablet or 30 drops 2 times a day) for 6 months. Patients of Group III were given for a postoperative rehabilitation Mastodynon® in a double dose (2 tablets or 60 drops 2 times a day) for 6 months.

Results. Surgical treatment without conservative therapy eliminates organic changes in the breast, but hormonal disorders that have led to pathologic and histological changes in the tissues of breast continue to exist for a long time and can lead to repeated nodal formations. In group І, 25% of patients within 2 years performed repeated sectoral resections on recurrence of nodule formation. The use of Mastodynon® in standard doses (group II) for postoperative rehabilitation contributes to a significant improvement in hormonal homeostasis (normalization of prolactin, estradiol and progesterone levels), a 24.7 mm decrease in the degree of cyclic mastodynia according to the visual analog scale (VAS), and the improvement of ultrasound scan picture of breast in 75% of patients. The most pronounced effect of this rehabilitation approach after the surgical treatment phase was noted for the use of Mastodynon® in double doses (2 tablets or 60 drops 2 times a day) in Group III. In these patients, the degree of reduction of cyclic mastodynia was 30 mm for VAS and positive changes in the tissues of breast were noted in 85% of patients.

Conclusion. Despite the presence of short-term side effects and rapid rebounding in the double-dose Mastodynon® group, our study showed better results than standard doses, faster and more stable therapeutic effect. Taking into account the results obtained, it can be argued that the use of high doses of Mastodynon® may be recommended to patients for the treatment of mastopathy.


mastopathy; postoperative rehabilitation; mastodynia; Mastodynon


Smolanka, I.I., Ljashenko, A.О. “Fibrocystic breast disease.” Women’s Doctor 1 (2007): 16.

Zaitsev, V.F., Nikolaenko, T.A., Sugak, S.V. “Surgeon tactic at the nodal lesions of breast.” Actual problems of clinical medicine MN (1999): 35–6.

Vysotskaya, I.V., Letyagin, V.P., Kim, E.A. “Dishormonal mammary dysplasia.” Mammology 2 (2006): 9–12.

Andreeva, E.N., Ledneva, E.V. “Key aspects of the etiology and pathogenesis of fibrocystic breast disease.” Obstetrics and Gynecology 6 (2002): 7–9.

Tagieva, T.T., Volobuev, A.I. “Using Mastodynon in women with fibrocystic breast disease.” Health of Ukraine 5 (2002).

Wuttke, W., Jarry, H., Christoffe, V., et al. “Chaste tree (Vitex agnus-castus) – Pharmacology and clinical indications.” Phytomedicine 10 (2003): 348–57.

GOST Style Citations

1.           Смоланка, І.І. Фіброзно-кістозна мастопатія / І.І. Смоланка, А.О. Ляшенко // Жіночий лікар. – 2007. – № 1. – С. 16.

2.           Зайцев, В.Ф. Тактика хірурга при вузлових утвореннях молочних залоз / В.Ф. Зайцев, Т.А. Ніколаєнко, С.В. Сугак // Актуальні проблеми клінічної медицини. – Мн., 1999. – С. 35–36.

3.           Высоцкая, И.В. Дисгормональные дисплазии молочных желез / И.В. Высоцкая, В.П. Летягин, Е.А. Ким // Маммология. – 2006. – № 2. – С. 9–12.

4.           Андреева, Е.Н. Основные аспекты этиологии и патогенеза фиброзно-кистозной болезни молочной железы / Е.Н. Андреева, Е.В. Леднева // Акушерство и гинекология. – 2002. – № 6. – С. 7–9.

5.           Тагиева, Т.Т. Применение Мастодинона у женщин с фиброзно-кистозной мастопатией / Т.Т. Тагиева, А.И. Волобуев // Здоров’я України. – 2002. – № 5.

6.           Wuttke, W., Jarry, H., Christoffe, V., et al. “Chaste tree (Vitex agnus-castus) – Pharmacology and clinical indications.” Phytomedicine 10 (2003): 348–57.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)